Atopic Dermatitis Clinical Trials in Chicago, Illinois

6 studies are recruiting for atopic dermatitis in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

   The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Atd002 52017, Chicago, Illinois

   Locations

   68 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT07277660 on ClinicalTrials.gov

2. A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupil…

   Stage

   Phase 3

   Ages

   2 to 11

   Site

   Northwestern University Feinberg School of Medicine /ID# 265117, Chicago, Illinois

   Locations

   150 in total

   Run by

   AbbVie

   See if you can join NCT06461897 on ClinicalTrials.gov

3. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   DeNova Research /ID# 264513, Chicago, Illinois

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov

4. Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

   This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic…

   Stage

   Phase 1

   Ages

   6 and older

   Site

   Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago, Illinois

   Locations

   8 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06504160 on ClinicalTrials.gov

5. Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

   Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

   Stage

   Phase 4

   Ages

   6 to 17

   Site

   Lurie Children's Hospital/Northwestern University, Chicago, Illinois

   Run by

   Northwestern University

   See if you can join NCT05042258 on ClinicalTrials.gov

6. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

   The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

   Stage

   Not phased

   Ages

   12 and older

   Site

   Galderma Investigational Site 7058, Chicago, Illinois

   Locations

   108 in total

   Run by

   Galderma R&D

   See if you can join NCT06988605 on ClinicalTrials.gov